Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | CFO | April 15, 2025 | April 16, 2025 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Financial Officer | August 06, 2026 | August 10, 2026 |
| Immunome Inc.IMNM · Entity 4219 | Chief Financial Officer | June 08, 2023 | June 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date April 15, 2025 · Filed April 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.11 · Expires 2035-04-14 | Direct | 143,907 |
Reported balance
After 2025-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-15 · Grant · Acquired 143,907 · Balance 143,907 F1: 1/48th of the shares subject to the option vest monthly following April 15, 2025, the vesting commencement date, subject to the Report Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest monthly following April 15, 2025, the vesting commencement date, subject to the Report Person's continuous service to the Issuer through each vesting date.
IOVANCE BIOTHERAPEUTICS, INC.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,995 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 49,995 · Balance 49,995 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 28,757 |
Reported balance
After 2026-08-06 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-06 · Tax withholding · Disposed 21,238 · Balance 28,757 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents the common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 100,005 |
Reported balance
After 2026-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-06 · Exercise / conversion · Disposed 49,995 · Balance 100,005 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on August 6, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents the common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on August 6, 2025, but does not include any other RSUs held by such Reporting Person.
Immunome Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2033-06-08 | Direct | 58,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 58,000 · Balance 58,000 F1: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 10, 2026 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 49,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-093482 · tm2622610-1_4seq1.xml · derivative · entry 3 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,005 Underlying: Common Stock · 49,995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on August 6, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 21,238 | $6.21 | $131,887.98 |
DisclosureSEC source: 0001104659-26-093482 · tm2622610-1_4seq1.xml · nonDerivative · entry 2 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,757 F2 · date: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 49,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-093482 · tm2622610-1_4seq1.xml · nonDerivative · entry 1 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:25 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 132,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-026475 · tm268453-5_4seq1.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,200 Underlying: Common stock · 132,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075687 · tm2522878-2_4seq1.xml · derivative · entry 2 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F1 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001104659-25-075687 · tm2522878-2_4seq1.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common stock · 300,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 143,907 | $0.00 Strike: $20.11 | $0.00 |
DisclosureSEC source: 0000950170-25-054737 · ownership.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,907 Underlying: Common Stock · 143,907 shares Expires 2035-04-14 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following April 15, 2025, the vesting commencement date, subject to the Report Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 13:29 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option (Right to Buy) · Derivative | 93,600 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0000950170-24-113418 · ownership.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,600 Underlying: Common Stock · 93,600 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following October 4, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | PurchaseCommon Stock | 2,000 | $19.00 | $38,000.00 |
DisclosureSEC source: 0000950170-24-009432 · ownership.xml · nonDerivative · entry 1 Roche Corleen M. · CIK 0001857905 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option · Derivative | 492,920 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007962 · ownership.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · CFO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,920 Underlying: Common Stock · 492,920 shares Expires 2034-01-10 F1 · derivative.exercise_date: The stock option vests as to 25% of the underlying shares on January 16, 2025, and as to the remaining of the underlying shares in 36 substantially similar monthly installments thereafter. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:58 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 58,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001104659-23-070411 · tm2318426-10_4seq1.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:06 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001104659-22-073103 · tm2218674-9_4seq1.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: With respect to the options to purchase 40,000 shares, 25% of the shares subject to such options vest on June 16, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to such options shall vest every month thereafter. With respect to the remaining options to purchase 30,000 shares, 50% of the shares subject to such options vest on June 16, 2023, and the remaining 50% of the shares subject to such options vest on June 16, 2024. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 23:21 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 16,609 | $0.00 Strike: $20.92 | $0.00 |
DisclosureSEC source: 0001104659-21-075235 · tm2118079-6_4seq1.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,609 Underlying: Common Stock · 16,609 shares Expires 2031-05-28 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on May 28, 2022, and one-thirty-sixth (1/36th) of the remaining shares subject to the option shall vest every month thereafter. Read SEC document |
| April 19, 2021 Filed Apr 22, 2021 01:38 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $27.53 | $0.00 |
DisclosureSEC source: 0001104659-21-053339 · tm2113705-2_4seq1.xml · derivative · entry 1 Roche Corleen M. · CIK 0001857905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-04-19 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on April 19, 2022, and the remaining 75% of shares subject to the option shall vest in equal monthly installments for the 36 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.